1. In Vivo

Lead From The Front – But Resist Micromanaging

An Interview With Rising Leader Greg Mullen, CEO of Theragnostics

 
• By Sten Stovall

Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.

Paper boat
• Source: Shutterstock

Shepherding radiopharmaceuticals start-up Theragnostics Ltd. up to and through a planned series A financing this year is a key strategic aim of its CEO Greg Mullen. The funding round will give the transatlantic biotech the financial runway to put its lead therapeutic product, an iodine-123 labeled PARP inhibitor, into clinical development as a targeted radionuclide therapy.

Called THG-009, the radiotherapeutic poly (ADP-ribose) polymerase inhibitor is designed to deliver doses of radiation to tumours, killing cancer cells...

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.